Instructions for Tazalok oral drops bottle 100 ml No. 3
Composition
active ingredients:
10 ml of the preparation contains a tincture of a mixture of medicinal plant raw materials (1:10): six-petaled meadowsweet roots (Filipendula vulgaris Moench) – 0.28 g, fresh curly parsley roots (Petroselini radix) – 0.225 g, fresh celery roots (Apiumi radix) – 0.17 g, true marjoram herb (Galii herba) – 0.135 g, common flax herb (Linariae herba) – 0.11 g, marigold flowers (Flores Calendulae) – 0.08 g (extractant – 40% ethanol).
Dosage form
Oral drops, solution.
Main physicochemical properties: transparent liquid from light brown to brown in color with a specific odor.
During storage, sediment formation is allowed.
Pharmacotherapeutic group
Means used in gynecology. ATX code G02СХ.
Pharmacological properties
Pharmacodynamics.
A herbal non-hormonal preparation with a complex action due to the synergistic effects of the components that make up the preparation and exhibit hormone-regulating, antiproliferative, anti-inflammatory, sedative and tonic effects. Flavonoids of biologically active substances of the preparation TazalokTM are similar in structure to endogenous estrogen, but do not exhibit estrogen-like activity, they have the ability to competitively bind to estrogen (androgen) receptors with an excess of estrogens (androgens) themselves or their receptors in target organs, change the activity of aromatase system enzymes, preventing the conversion of androgens into estrogens. Thus, TazalokTM exhibits selective antiestrogenic activity, promotes rhythmic production and normalization of the ratio of gonadotropic hormones, reduces prolactin levels and increases progesterone levels, eliminates the imbalance between estradiol and progesterone, normalizes the second phase of the menstrual cycle. It has a pronounced effect on the glandular tissue and stromal elements of the mammary glands, ovaries and uterus, exhibits antiproliferative and anti-inflammatory properties, prevents the development of dysplastic processes in these tissues. In polycystic ovarian disease, it helps soften the cyst capsule, reduce its tension due to the resorptive effect, and enhance the function of the intact part of the ovary. It promotes active resorption of cyst contents, resorption of painless dense nodes in the mammary glands, and reduces the reaction of the mammary glands to the phases of the menstrual cycle. It exhibits antispasmodic properties, analgesic and sedative effects. Biologically active molecules of the drug TazalokTM have the ability to induce and enhance apoptosis, block the action of growth factors, and inhibit angiogenesis.
Pharmacokinetics.
Pharmacokinetic data are not available.
Indication
Menstrual cycle disorders; premenstrual syndrome; algodysmenorrhea; dysmenorrhea; fibrocystic mastopathy; ovarian retention cysts. As part of complex therapy, it is used for endometrial hyperplasia, uterine fibroids, endometriosis; polycystic ovary syndrome.
Contraindication
Hypersensitivity to any components of the drug.
Interaction with other medicinal products and other types of interactions
If you need to take any other medications, you should inform your doctor.
Use during pregnancy or breastfeeding
Do not use during pregnancy or breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Method of administration and doses
30–40 drops of the drug should be diluted in ½ cup of boiled water at room temperature. Take 30 minutes before meals 3 times a day. TazalokTM should be taken for at least 3 months, without a break during menstruation. The daily dose can be divided into 2 doses. If complaints recur after discontinuation of the drug, therapy should be continued after consulting a doctor.
Children
The drug should not be used in children, as the efficacy and safety of the drug have not been established.
Overdose
Cases of overdose of the drug are unlikely. However, cardiovascular system disorders are possible. Treatment: gastric lavage, use of activated charcoal, symptomatic therapy.
Side effects
On the skin, hypersensitivity reactions and allergic reactions may sometimes occur, including skin rashes, hyperemia, itching, swelling of the skin, and infiltrated hyperemic spots.
If any adverse reactions occur, discontinue use of the drug and consult a doctor.
Expiration date
2.5 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
50 ml in a bottle, 1 bottle in a cardboard box.
100 ml in a bottle. 1 bottle in a cardboard box. 2 or 3 bottles in a cardboard box with a separate insert.
Vacation category
Without a prescription.
Producer
Dr. Gustav Klein GmbH & Co. KG.
Dr. Gustav Klein GmbH & Co. KG.
Steinenfeld 3, 77736 Zell am Harmersbach, Germany.
Steinenfeld 3, 77736, Zell am Harmersbach, Germany.
Applicant
LLC "UNIVERSAL AGENCY "PRO-PHARMA".
